Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice.

Rivat C, Sar C, Mechaly I, Leyris JP, Diouloufet L, Sonrier C, Philipson Y, Lucas O, Mallié S, Jouvenel A, Tassou A, Haton H, Venteo S, Pin JP, Trinquet E, Charrier-Savournin F, Mezghrani A, Joly W, Mion J, Schmitt M, Pattyn A, Marmigère F, Sokoloff P, Carroll P, Rognan D, Valmier J.

Nat Commun. 2018 Mar 12;9(1):1042. doi: 10.1038/s41467-018-03496-2.

2.

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

Zhao B, Zhao H.

Oncotarget. 2017 Sep 23;8(55):93813-93824. doi: 10.18632/oncotarget.21217. eCollection 2017 Nov 7.

3.

Developmental and Functional Control of Natural Killer Cells by Cytokines.

Wu Y, Tian Z, Wei H.

Front Immunol. 2017 Aug 4;8:930. doi: 10.3389/fimmu.2017.00930. eCollection 2017. Review.

4.

Deletion of Batf3-dependent antigen-presenting cells does not affect atherosclerotic lesion formation in mice.

Gil-Pulido J, Cochain C, Lippert MA, Schneider N, Butt E, Amézaga N, Zernecke A.

PLoS One. 2017 Aug 3;12(8):e0181947. doi: 10.1371/journal.pone.0181947. eCollection 2017.

5.

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, Xu M, Yang FC, Zhao ZJ.

Stem Cell Investig. 2017 Jun 2;4:48. doi: 10.21037/sci.2017.05.04. eCollection 2017. Review.

6.

FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche.

Williams KM, Moore AR, Lucas PJ, Wang J, Bare CV, Gress RE.

Exp Hematol. 2017 Aug;52:40-49. doi: 10.1016/j.exphem.2017.05.005. Epub 2017 May 26.

PMID:
28552733
7.

The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.

Tsapogas P, Mooney CJ, Brown G, Rolink A.

Int J Mol Sci. 2017 May 24;18(6). pii: E1115. doi: 10.3390/ijms18061115. Review.

8.

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S.

Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17.

9.

Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Rebechi MT, Pratz KW.

Leuk Lymphoma. 2017 Sep;58(9):1-11. doi: 10.1080/10428194.2017.1283031. Epub 2017 Feb 6.

PMID:
28278729
10.

FLT3 inhibitors: clinical potential in acute myeloid leukemia.

Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J.

Onco Targets Ther. 2017 Feb 3;10:607-615. doi: 10.2147/OTT.S103790. eCollection 2017. Review.

11.

Permissive roles of cytokines interleukin-7 and Flt3 ligand in mouse B-cell lineage commitment.

von Muenchow L, Alberti-Servera L, Klein F, Capoferri G, Finke D, Ceredig R, Rolink A, Tsapogas P.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8122-E8130. Epub 2016 Nov 29.

12.

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.

DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GG, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK.

Clin Cancer Res. 2017 Mar 15;23(6):1481-1492. doi: 10.1158/1078-0432.CCR-16-1330. Epub 2016 Sep 20. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3971-3972.

13.

Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1.

Fraszczak J, Helness A, Chen R, Vadnais C, Robert F, Khandanpour C, Möröy T.

PLoS One. 2016 Jul 28;11(7):e0160344. doi: 10.1371/journal.pone.0160344. eCollection 2016.

14.

Macrophage colony-stimulating factor receptor marks and regulates a fetal myeloid-primed B-cell progenitor in mice.

Zriwil A, Böiers C, Wittmann L, Green JC, Woll PS, Jacobsen SE, Sitnicka E.

Blood. 2016 Jul 14;128(2):217-26. doi: 10.1182/blood-2016-01-693887. Epub 2016 May 17.

15.

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK.

JCI Insight. 2016 Mar;1(3):e85630.

16.

Expression of GADS enhances FLT3-induced mitogenic signaling.

Chougule RA, Cordero E, Moharram SA, Pietras K, Rönnstrand L, Kazi JU.

Oncotarget. 2016 Mar 22;7(12):14112-24. doi: 10.18632/oncotarget.7415.

17.

Transcriptional Control of Dendritic Cell Development.

Murphy TL, Grajales-Reyes GE, Wu X, Tussiwand R, Briseño CG, Iwata A, Kretzer NM, Durai V, Murphy KM.

Annu Rev Immunol. 2016 May 20;34:93-119. doi: 10.1146/annurev-immunol-032713-120204. Epub 2015 Dec 23. Review.

18.

TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality.

Wang J, Li T, Zhou M, Hu Z, Zhou X, Zhou S, Wang N, Huang L, Zhao L, Cao Y, Xiao M, Ma D, Zhou P, Shang Z, Zhou J.

Sci Rep. 2015 Dec 16;5:18454. doi: 10.1038/srep18454.

19.

Murine germinal center B cells require functional Fms-like tyrosine kinase 3 signaling for IgG1 class-switch recombination.

Svensson MN, Andersson KM, Wasén C, Erlandsson MC, Nurkkala-Karlsson M, Jonsson IM, Brisslert M, Bemark M, Bokarewa MI.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):E6644-53. doi: 10.1073/pnas.1514191112. Epub 2015 Nov 16.

20.

Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

Huang Y, Elliott MJ, Yolcu ES, Miller TO, Ratajczak J, Bozulic LD, Wen Y, Xu H, Ratajczak MZ, Ildstad ST.

Am J Transplant. 2016 Feb;16(2):440-53. doi: 10.1111/ajt.13511. Epub 2015 Nov 9.

Supplemental Content

Support Center